AHA’s 340B Rebate Lawsuit: What the New Filings Mean for 2027

The American Hospital Association (AHA), the Maine Hospital Association and four hospitals have returned to federal court to challenge the revised 340B rebate pilot. Their October 9 complaint seeks to set aside the program and its manufacturer approvals before implementation. The case is American Hospital Association et al. v. Kennedy et al., No. 1:26-cv-00515-LEW, in the District of Maine. ^[1]

As of November 5, briefing on preliminary relief is ongoing, and HRSA continues to list January 1, 2027 as the pilot’s start date. Covered entities should keep that date in their planning while following the court’s next steps. ^{[3] [8]}

Why grantees should follow this case

The plaintiff hospitals are challenging a program that can also affect grantee purchasing and pharmacy operations. Under the pilot, covered entities would obtain the 340B price for participating products through rebates after paying wholesale acquisition cost (WAC). Entity exceptions depend on the applicable approved manufacturer plan. ^[3]

The National Association of Community Health Centers and National PCA Hub brought the health-center perspective to the court in an October 29 amicus brief—a filing by organizations supporting the plaintiffs without becoming plaintiffs themselves. They argue that HRSA did not adequately address health centers’ sliding-fee obligations, Medicaid acquisition-cost reimbursement, physical inventory needs and restrictions on the use of health-center resources. ^[6]

Those arguments concern health centers specifically; other grantees should assess their own grant requirements and operating arrangements. For a program manager, the useful question is where the proposed payment sequence intersects with the organization’s medication access, inventory and billing processes.

What AHA is challenging

The complaint raises seven claims under the Administrative Procedure Act (APA), which governs federal agency decision-making. Among the plaintiffs’ allegations are that HRSA underestimated costs, overstated benefits, failed to adequately consider less burdensome alternatives and did not properly account for covered entities’ longstanding reliance on upfront discounts. The complaint also challenges differences among the approved manufacturer plans. These are allegations for the court to resolve. ^[1]

The injunction motion develops the operational argument. The plaintiffs say the work extends beyond preparing and transmitting claims: organizations must reconcile payments, investigate denials, correct records, train staff and manage vendor relationships. They also argue that financing costs reach beyond interest expense to include cash reserves, credit arrangements and resources diverted from patient services. ^[2]

The payment timeline is central to that dispute. The plaintiffs contend that wholesaler payment obligations can arrive before a complete rebate claim is ready, and that inventory may remain on the shelf before dispensing. They ask the court to halt implementation while the challenge proceeds. ^[2]

The government’s November 3 response

The government argues that HRSA corrected the shortcomings of the earlier pilot by gathering public comments and explaining its decision in a substantially fuller administrative record. It maintains that the statute permits rebates and that the agency reasonably weighed costs, benefits, reliance interests and alternatives. It also argues that the pilot can improve program integrity and prevent overlapping 340B discounts and Medicare negotiated-price concessions. ^[5]

On administration, the government defends HRSA’s estimate of an average five hours of reporting work per week per covered entity. It emphasizes standardized data, information already maintained by covered entities and a common submission platform. On liquidity, it argues that the plaintiffs have not established irreparable harm and points to their financial resources and affiliated entities. Those are the government’s positions, rather than findings by the court. ^[5]

This leaves a practical issue at the center of the case: how closely the agency’s assumptions match the work and financing needs of actual covered entities.

Where the case stands

The earlier pilot was enjoined in December 2025; its notices and approvals were vacated in February 2026. This lawsuit concerns HRSA’s revised program for 2027. ^[3]

The reply deadline is the next scheduled briefing milestone. It is not a promised decision date. The scope and timing of any relief will depend on the court’s order.

What to prepare while the case proceeds

340B Auditor recommends keeping a short, organization-specific readiness file that can support decisions as the litigation develops:

• Map the affected purchases. Identify the products, purchasing accounts, dispensing settings and vendor responsibilities relevant to your program.
• Test the full claims workflow. Have pharmacy, billing and your third-party administrator identify who extracts data, resolves exceptions and matches submissions to payments.
• Measure the cash interval. Model your own ordering, wholesaler payment, dispensing and submission dates. Include a scenario with corrections or delayed payment.
• Record the assumptions. Keep vendor estimates, expected staff time and unresolved questions together so the team can revise its plan when new guidance or an order arrives.

HRSA’s ten-calendar-day payment-or-denial deadline runs from a completed data submission. An incomplete submission can restart that clock when the required data are resubmitted. It does not establish a ten-day interval from purchase to receipt of cash. ^[3]

Our Beacon registration guide and claims submission guide can help organize that work. For help reviewing your program’s purchasing and data processes, contact 340B Auditor.